eth47
Gene therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 29, 2023 (NCT07055321)
Timeline
Indications
Studied for
Mechanism of action
- Interferon lambda receptorAGONIST
Interferon lambda receptor agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07059767 | Phase 2 | Jun 24, 2025 | Ethris GmbH, Virtus Pharms |
| NCT07055321 | Phase 1 | Nov 29, 2023 | Ethris GmbH |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ethris GmbH | For profit | 2 | 2 | 2 | 2023 |
| Virtus Pharms | For profit | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1